DAXISPHARMA

DAXISPHARMA has been active since 1980 and the Belgian State Gazette contains no insolvency or warning signals. The 2025 annual accounts show equity of €6.0m and a net result of €166,396. Equity remains stable across the filed fiscal years (±1.9% per year). Its solvency ranks better than 26% of 6,033 sector peers (NACE 46, fiscal year 2025). The computed 12-month bankruptcy probability is 1.3% (low).